Pivikto 200MG-50MG Tablet (14’s) is a specialized medication primarily composed of Alpelisib, a targeted therapy used in the treatment of certain types of breast cancer. This drug is particularly effective for patients with hormone receptor-positive, HER2-negative breast cancer that has progressed following prior treatment. Pivikto works by inhibiting the PI3K pathway, which is often activated in cancer cells, leading to uncontrolled growth and proliferation. Each tablet contains 200 mg of Alpelisib, along with other excipients that aid in its formulation. The medication is designed to be taken in conjunction with other therapies, such as endocrine treatment, to enhance its efficacy. Pivikto is available in a pack of 14 tablets, making it convenient for patients to manage their treatment regimen. As a targeted therapy, it represents a significant advancement in personalized medicine, aiming to improve outcomes for patients with specific genetic markers associated with their cancer.